Pyxis Oncology Q2 net loss $15.9M; cash $144.1M; Apexigen deal on track for August close

Pyxis Oncology, Inc.

2023-Q2 EPS reported -$0.95

Net loss $15.9M ($0.41/share) vs $25.6M ($0.79) in Q2 2022; loss narrowed on lower R&D and G&A.
Cash and short-term investments $144.1M as of June 30, 2023; expected runway into first half of 2025.
R&D expenses $11.4M (down from $17.2M YoY); G&A $6.7M (down from $8.6M YoY).
Third dose cohort initiated in Phase 1 trial of ADC PYX-201; three European sites recruiting.
Apexigen acquisition expected to close later in August 2023; sotigalimab development plan in Q4.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Pyxis Oncology, Inc. reported the quarter ended June 30, 2023 results: net income $15.9 million, EPS $0.41 per common share.

Period: the quarter ended June 30, 2023
Net income: $15.9 million
EPS: $0.41 per common share
Result: reported results

Exact text from the filing

Net loss was $15.9 million, or $0.41 per common share, for the three months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041601

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.